| Apixaban versus warfarin in patients with atrial fibrillation CB Granger, JH Alexander, JJV McMurray, RD Lopes, EM Hylek, ... New England Journal of Medicine 365 (11), 981-992, 2011 | 11249 | 2011 |
| Edoxaban versus warfarin in patients with atrial fibrillation RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ... New England Journal of Medicine 369 (22), 2093-2104, 2013 | 6081 | 2013 |
| Eplerenone in patients with systolic heart failure and mild symptoms F Zannad, JJV McMurray, H Krum, DJ van Veldhuisen, K Swedberg, H Shi, ... New England Journal of Medicine 364 (1), 11-21, 2011 | 3832 | 2011 |
| Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study K Swedberg, M Komajda, M Böhm, JS Borer, I Ford, A Dubost-Brama, ... The Lancet 376 (9744), 875-885, 2010 | 3446 | 2010 |
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes WB White, CP Cannon, SR Heller, SE Nissen, RM Bergenstal, GL Bakris, ... New England Journal of Medicine 369 (14), 1327-1335, 2013 | 3176 | 2013 |
| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2566 | 2017 |
| Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Marcus D. Flather, Marcelo C. Shibata, Andrew J.S. Coats, on behalf of the ... European Heart Journal 26 (3), 215-225, 2005 | 2391 | 2005 |
| Long-term use of ticagrelor in patients with prior myocardial infarction MP Bonaca, DL Bhatt, M Cohen, PG Steg, RF Storey, EC Jensen, ... New England Journal of Medicine 372 (19), 1791-1800, 2015 | 2247 | 2015 |
| Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial K Fox, I Ford, PG Steg, M Tendera, R Ferrari, B Investigators, ... The Lancet 372 (9641), 807-816, 2008 | 1491 | 2008 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 987 | 2018 |
| Tiotropium versus salmeterol for the prevention of exacerbations of COPD C Vogelmeier, B Hederer, T Glaab, H Schmidt, MPMH Rutten-van Mölken, ... New England Journal of Medicine 364 (12), 1093-1103, 2011 | 981 | 2011 |
| Ivabradine in stable coronary artery disease without clinical heart failure K Fox, I Ford, PG Steg, JC Tardif, M Tendera, R Ferrari, SIGNIFY, ... New England Journal of Medicine 371 (12), 1091-1099, 2014 | 639 | 2014 |
| Darapladib for preventing ischemic events in stable coronary heart disease Stability Investigators New England Journal of Medicine 370 (18), 1702-1711, 2014 | 581 | 2014 |
| Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial JC Tardif, P Ponikowski, T Kahan, ASSOCIATE, study Investigators, ... European Heart Journal 5 (30), 540–548, 2009 | 529 | 2009 |
| Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial SJ Connolly, JW Eikelboom, J Bosch, G Dagenais, L Dyal, F Lanas, ... The Lancet 391 (10117), 205-218, 2018 | 415 | 2018 |
| Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized … M Jadzinsky, A Pfützner, E Paz‐Pacheco, Z Xu, E Allen, R Chen, ... Diabetes, Obesity and Metabolism 11 (6), 611-622, 2009 | 400 | 2009 |
| Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial JD Easton, RD Lopes, MC Bahit, DM Wojdyla, CB Granger, L Wallentin, ... The Lancet Neurology 11 (6), 503-511, 2012 | 383 | 2012 |
| Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Rydén L ... Atherosclerosis 285, 135-146, 2019 | 356 | 2019 |
| Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme … K Kotseva, G De Backer, D De Bacquer, L Rydén, A Hoes, D Grobbee, ... European Journal of Preventive Cardiology 28 (4), 370-9, 2021 | 179 | 2021 |
| Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial Markus P Schlaich , Marc Bellet , Michael A Weber , Parisa Danaietash ... Lancet 400 (10367), 1927-1937, 2022 | 123 | 2022 |
Maryna DolzhenkoShupyk National Medical Academy of Postgraduate Education, CardiologyПідтверджена електронна адреса в nmapo.edu.ua
